Cited by 327Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Pratley, Richard E, Nauck, Michael A, Barnett, Anthony H, Feinglos, Mark N, Ovalle, Fernando, Harman-Boehm, Illana, Ye, June, Scott, Rhona, Johnson, Susan, Stewart, Murray, Rosenstock, Julio·2014·The Lancet Diabetes & Endocrinology

DOI 10.1016/s2213-8587(13)70214-6

Open this paper in CoChat — free account

Abstract

Background As new members of a drug class are developed, head-to-head trials are an important strategy to guide personalised treatment decisions. We assessed two glucagon-like peptide-1 receptor agonists, once-weekly albiglutide and once-daily liraglutide, in patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. Methods We undertook this 32-week, open-label, phase 3 non-inferiority study at 162 sites in eight countries: USA (121 sites), Australia (9 sites), Peru (7 sites), Philippines (7 sites), South Korea (5 sites), UK (5 sites), Israel (4 sites), and Spain (4 sites). 841 adult participants (aged ≥18 years) with inadequately controlled type 2 diabetes and a BMI between 20 and 45 kg/m(2) were enrolled and randomised in a 1:1 ratio to receive albiglutide 30 mg once weekly titrated to 50 mg at week 6, or liraglutide 0·6 mg once daily titrated to 1·2 mg at week 1 and 1·8 mg at week 2. The randomisation schedule was generated by an independent randomisation team by the permuted block method with a fixed block size of 16. Participants and investigators were unmasked to treatment. The primary endpoint was change from baseline in HbA1c for albiglutide versus liraglutide, with a 95% CI non-inferiority upper margin of 0·3%. The primary analysis was by modified intention to treat. The study is registered with ClinicalTrials.gov, number NCT01128894. Findings 422 patients were randomly allocated to the albigultide group and 419 to the liraglutide group; 404 patients in the abliglutide group and 408 in the liraglutide group received the study drugs. The primary endpoint analysis was done on the modified intention-to-treat population, which included 402 participants in the albiglutide group and 403 in the liraglutide group. Model-adjusted change in HbA1c from baseline to week 32 was -0·78% (95% CI -0·87 to -0·69) in the albigludite group and -0·99% (-1·08 to -0·90) in the liraglutide group; treatment difference was 0·21% (0·08-0·34; non-inferiority p value=0·0846). Injection-site reactions occurred in more patients given albiglutide than in those given liraglutide (12·9% vs 5·4%; treatment difference 7·5% [95% CI 3·6-11·4]; p=0·0002), whereas the opposite was the case for gastrointestinal events, which occurred in 49·0% of patients in the liraglutide group versus 35·9% in the albiglutide group (treatment difference -13·1% [95% CI -19·9 to -6·4]; p=0·00013). Interpretation Patients who received once-daily liraglutide had greater reductions in HbA1c than did those who received once-weekly albiglutide. Participants in the albiglutide group had more injection-site reactions and fewer gastrointestinal events than did those in the liraglutide group. Funding GlaxoSmithKline.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(13)70214-6

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citation
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citation
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citation
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Self-citation
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 821
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Self-citation

Show all 24 references

Research works printed but not linked: 1

Rosenstock, 2010, Albiglutide, Drugs Fut, 35, 701, 10.1358/dof.2010.35.9.1516042 · DOI

Sorted by citations

Items 101–200 of 327

Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 45
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Home, P., Åhrén, B., Reusch, J. E. B., Rendell, M., Weissman, P. N., Cirkel, D. T., Miller, D. M., Ambery, P., Carr, M. C., & Nauck, M. A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.013 · Cited by 42
Self-citation
Dulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 44
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Self-citation
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 40
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
Janež, A., Muzurović, E. M., Stoian, A. P., Haluzı́k, M., Guja, C., Czupryniak, L., Duvnjak, L. S., Lalic, N. M., Tankova, T. I., Bogdański, P., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.017 · Cited by 42
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A meta‐analysis and meta‐regression analysis
Yoshiji, S., Minamino, H., Tanaka, D., Yamane, S., Harada, N., & Inagaki, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14666 · Cited by 40
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Cardoso, P., Young, K., Nair, A. T. N., Hopkins, R., McGovern, A. P., Haider, E., Karunaratne, P., Donnelly, L. A., Mateen, B. A., Sattar, N. A., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06099-3 · Cited by 40
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
Albumin-binding domain extends half-life of glucagon-like peptide-1
Tan, H., Su, W., Zhang, W., Zhang, J., Sattler, M., & Zou, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173650 · Cited by 40
What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue
Klair, N., Patel, U. P., Saxena, A., Patel, D. N., Ayesha, I. E., Monson, N. R., & Ramphall, S. (2023) · Cureus · doi:10.7759/cureus.46197 · Cited by 46
Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Blair, H. A., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0370-5 · Cited by 37
Incretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 38
The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis
Alhindi, Y., & Avery, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100944 · Cited by 41
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 37
Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus
Knudsen, L. B., Secher, A., Hecksher‐Sørensen, J., & Pyke, C. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12463 · Cited by 38
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial
Zang, L., Liu, Y., Geng, J., Luo, Y. M., Bian, F., Lv, X., Yang, J., Liu, J., Peng, Y., Li, Y., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12674 · Cited by 37
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Nauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
Self-citation
Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Babenko, A. Y., Savitskaya, D. A., Kononova, Y. A., Trofimova, A. Y., Симаненкова, А. В., Vasilyeva, E. Y., & Shlyakhto, E. V. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1365162 · Cited by 38
Obesity and GLP-1
de, A. P.-M., Pellitero, S., & Puig‐Domingo, M. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03369-6 · Cited by 36
GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Jaarah, D., Zoubi, M. S. A., Abdelhady, G. T., Rabi, F., & Tambuwala, M. M. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211051697 · Cited by 37
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes ( LIRA‐SWITCH ): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial
Bailey, T. S., Takács, R., Tinahones, F. J., Rao, P. V., Tsoukas, G. M., Thomsen, A. B., Kaltoft, M. S., & Maislos, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12736 · Cited by 35
Bariatric surgery – time to replace with GLP-1?
Webb, D., Abrahamsson, N., Sundbom, M., & Hellström, P. M. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1293154 · Cited by 38
Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review
Cimmaruta, D., Maiorino, M. I., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
GLP-1 receptor agonists: differentiation within the class
Taylor, S. I. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30413-8 · Cited by 33
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 33
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials
Monami, M., Dicembrini, I., Nreu, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1054-2 · Cited by 32
Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery
Ichimizu, S., Watanabe, H., Maeda, H., Hamasaki, K., Nakamura, Y., Chuang, V. T. G., Kinoshita, R., Nishida, K., Tanaka, R., Enoki, Y., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.037 · Cited by 32
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
Albiglutide does not impair the counter‐regulatory hormone response to hypoglycaemia: a randomized, double‐blind, placebo‐controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus
Hompesch, M., Jones-Leone, A. R., Carr, M. C., Matthews, J., Zhi, H., Young, M. A., Morrow, L., & Reinhardt, R. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12398 · Cited by 31
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation
Yu, M. B., Xie, J., Landó, L. F., Kabul, S., & Swindle, R. W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.11.017 · Cited by 30
Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide
Brønden, A., Knop, F. K., & Christensen, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0499-8 · Cited by 31
Efficacy and safety of polyethylene glycol loxenatide as add‐on to metformin in patients with type 2 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3b trial
Gao, F., Lv, X., Mo, Z., Ma, J., Zhang, Q., Yang, G., Liu, W., Li, Q., Zhou, J., Bao, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14163 · Cited by 32
Rational Design of a Humanized Glucagon‐Like Peptide‐1 Receptor Agonist Antibody
Zhang, Y., Zou, H., Wang, Y., Caballero, D., González, J., Chao, E., Welzel, G., Shen, W., Wang, D., Schultz, P. G., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201410049 · Cited by 30
Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes
Unni, S. K., Wittbrodt, E. T., Ma, J., Schauerhamer, M. B., Hurd, J., Ruiz‐Negrón, N., & McAdam‐Marx, C. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13107 · Cited by 30
An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning.
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 30
Targeting orphan G protein‐coupled receptors for the treatment of diabetes and its complications: C‐peptide and GPR 146
Kolar, G. R., Grote, S., & Yosten, G. L. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12528 · Cited by 31
A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons
Smith, W. B., Nguyen, D., Clough, T., Schofield, J. P., Kagan, M. R., Kompa, J., He, Y., Maratos–Flier, E., Jamontt, J., Vong, L., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae550 · Cited by 30
Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations
Carris, N. W., Taylor, J. R., & Gums, J. G. (2014) · Drugs · doi:10.1007/s40265-014-0325-2 · Cited by 28
A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial
Emoto, M., Terauchi, Y., Ozeki, A., Oura, T., Takeuchi, M., & Imaoka, T. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0401 · Cited by 29
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 37
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
Razavi-Nematollahi, L., & Ismail‐Beigi, F. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1266-7 · Cited by 31
GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 32
A personalized medication management platform (PMMP) to improve medication adherence: A randomized control trial
Huang, C.-Y., Nguyen, P., Clinciu, D., Hsu, C.-K., Lu, R., Yang, H.-C., Wu, C.-C., Tsai, W.-C., Chou, Y.-C., Kuo, T. B. J., et al. (2017) · Comput. Methods Programs Biomed. · doi:10.1016/j.cmpb.2016.12.012 · Cited by 25
Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
Orme, M. E., Nguyen, H. P., Lu, J., & Thomas, S. V. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s116810 · Cited by 27
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 27
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 35
Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide
Young, M. A., Wald, J. A., Matthews, J. E., Yang, F., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2754 · Cited by 26
Once-weekly albiglutide in the management of type 2 diabetes: patient considerations
Anderson, S. L., & Woodward, H. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s53075 · Cited by 26
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
Chatterjee, S., Ghosal, S., & Chatterjee, S. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i18.441 · Cited by 28
GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?
Zweck, E., & Roden, M. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30351-6 · Cited by 26
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 30
SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 25
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573010 · Cited by 27
Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials
Åhrén, B., Carr, M. C., Murphy, K., Perkins, C., Rendell, M., Mallory, J. M., Wilson, T. H., & JOHNSON, S. L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.017 · Cited by 25
Self-citation
Gastrointestinal peptides in eating-related disorders
Smith, K., & Moran, T. H. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113456 · Cited by 25
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients
Buysschaert, M., D’Hooge, D., & Preumont, V. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.05.001 · Cited by 23
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 23
Albiglutide: a unique GLP-1 receptor agonist
Rendell, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 24
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
Chudleigh, R. A., Platts, J. K., & Bain, S. C. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s193693 · Cited by 23
Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy
Chiefari, E., Capula, C., Vero, A., Oliverio, R., Puccio, L., Liguori, R., Pullano, V., Greco, M., Foti, D., Tirinato, D., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0412 · Cited by 22
Effect of Albiglutide on Cholecystokinin‐Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study
Shaddinger, B. C., Young, M. A., Billiard, J., Collins, D. A., Hussaini, A., & Nino, A. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.940 · Cited by 22
Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 30
A real‐world study of treatment patterns and outcomes in US managed‐care patients with type 2 Diabetes initiating injectable therapies
Wei, W., Buysman, E. K., Grabner, M., Xie, L., Brekke, L. N., Ke, X., Chu, J. W., & LEVIN, P. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12828 · Cited by 21
Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials
Xue, X., Ren, Z., Zhang, A., Yang, Q., Zhang, W., & Liu, F. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12847 · Cited by 22
Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery
Pechenov, S., Bhattacharjee, H., Yin, D., Mittal, S., & Subramony, J. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.01.006 · Cited by 22
Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: R eview of current strategies
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 22
Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials
Alfayez, O. M., Almutairi, A. R., Aldosari, A. A., & Yami, M. S. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.003 · Cited by 21
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
Giorgino, F., Bonadonna, R. C., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2775 · Cited by 19
Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 21
Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 23
Evaluation of the long‐term cost‐effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting
Hunt, B., Vega-Hernandez, G., Valentine, W. J., & Kragh, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12890 · Cited by 20
Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy
Brønden, A., Naver, S. V., Knop, F. K., & Christensen, M. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1068288 · Cited by 20
Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor Agonists
Lindamood, C., & Taylor, J. R. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.01.003 · Cited by 20
Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
Hedrington, M. S., Tsiskarishvili, A., & Davis, S. N. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1439014 · Cited by 21
Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus
Billings, L. K., Handelsman, Y., HEILE, M. K., Schneider, D., & Wyne, K. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s30 · Cited by 21
Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Deng, W.-Y., Zhao, Z., Zou, T., Kuang, T.-D., & Wang, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421527 · Cited by 21
Albiglutide: Is a better hope against diabetes mellitus?
Sharma, A. K., Veeraveedu, P. T., & Rajput, S. K. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.015 · Cited by 19
Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 17
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 18
Safety and Efficacy of Weight‐Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug‐Drug Interactions with Antiretroviral Therapy
Cope, R. J., Fischetti, B., Kavanagh, R., Lepa, T. M., & Sorbera, M. A. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2342 · Cited by 17
Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus
Davis, P. N., Ndefo, U. A., Oliver, A., & Payton, E. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140260 · Cited by 17
The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 16
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points
Yabe, D., Kuwata, H., Usui, R., Kurose, T., & Seino, Y. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1045471 · Cited by 16
Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability
Lally, J., Loughlin, A. O., Stubbs, B., Guérandel, A., O'Shea, D. B., & Gaughran, F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445968 · Cited by 18
Efficacy and safety of GLP-1 agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials
Messak, M., Abdelmageed, A., Senbel, A. A., Khattab, Y. A., Mandour, Y., Shaker, O., Rehan, A. H., Oransa, S., Nasr, M., Shabeeb, A. E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03932-3 · Cited by 16
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Self-citation
Subcutaneous adipose tissue composition and function are unaffected by liraglutide‐induced weight loss in adults with type 1 diabetes
Wegeberg, A., Meldgaard, T., Bæk, A., Drewes, A. M., Vyberg, M., Jessen, N., Brock, B., & Brock, C. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13575 · Cited by 16
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
Galstyan, G. R., Анатольевна, К. Е., & Александровна, Ю. Е. (2017) · Diabetes Mellitus · doi:10.14341/dm8804 · Cited by 17
Gastrointestinal safety across the albiglutide development programme
Leiter, L., Mallory, J. M., Wilson, T. H., & Reinhardt, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12679 · Cited by 13

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
Weissman, P. N., Carr, M. C., Ye, J., Cirkel, D. T., Stewart, M. W., Perry, C., & Pratley, R. E. (2014) · Diabetologia · doi:10.1007/s00125-014-3360-3 · Cited by 136
Self-citation
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide ( HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
Reusch, J. E. B., Stewart, M. W., Perkins, C. M., Cirkel, D. T., Ye, J., Perry, C., Reinhardt, R., & Bode, B. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12382 · Cited by 110
Self-citation
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
Blonde, L., JENDLE, J. H., Gross, J. L., Woo, V. C., Jiang, H. H., Fahrbach, J. L., & Miličević, Z. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60936-9 · Cited by 230
Weekly glucagon‐like peptide‐1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled study
Nino, A., Okuda, I., Wilson, T. H., Yue, L., Nakajima, H., Tsuboi, M., Carr, M. C., & Seino, Y. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12749 · Cited by 8

See all

Authors: Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., & Rosenstock, J.
Affiliations: Sanford Burnham Prebys Medical Discovery Institute (US)
Diabeteszentrum Bad Lauterberg (DE)
Heartlands Hospital (GB)
Duke University (US)
University of Alabama at Birmingham (US)
GlaxoSmithKline (United Kingdom) (GB)
GlaxoSmithKline (United States) (US)
Corresponding author: Pratley, Richard E
ORCID: Pratley, Richard E
Nauck, Michael A
Barnett, Anthony H
Ovalle, Fernando
Johnson, Susan
Rosenstock, Julio
Venue: The Lancet Diabetes & Endocrinology
Publisher: Elsevier BV
Published: 2014-04
Volume: 2
Issue: 4
Pages: 289-297
ISSN: 2213-8587 (ISSN-L)
DOI: 10.1016/s2213-8587(13)70214-6
OpenAlex: W2128825255
Cited by: 326
References: 24
Citations by year: 2026: 8 · 2025: 22 · 2024: 18 · 2023: 6 · 2022: 8 · 2021: 19 · 2020: 14 · 2019: 22 · 2018: 30 · 2017: 46 · 2016: 51 · 2015: 47 · 2014: 34
FWCI: 48.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Diabetes & Endocrinology (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
ANU Open Research (Australian National University) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: GlaxoSmithKline
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: type 2 diabetes, albiglutide, liraglutide, GLP-1 receptor agonists, HbA1c, inadequate glycemic control, oral antidiabetic drugs, non-inferiority, dose titration, head-to-head comparison, personalized treatment, body mass index, adverse events
MeSH terms: Liraglutide, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks